Published in JAKSTAT on April 16, 2013
JAK inhibition and progressive kidney disease. Curr Opin Nephrol Hypertens (2015) 0.98
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. Oncotarget (2015) 0.96
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther (2013) 0.88
Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem (2014) 0.87
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci (2016) 0.80
A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget (2016) 0.80
CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation. Oncotarget (2016) 0.80
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. J Clin Invest (2016) 0.75
Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3. Virology (2016) 0.75
Upregulation of TPX2 by STAT3: identification of a novel STAT3 binding site. PLoS One (2014) 0.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
Stat3 as an oncogene. Cell (1999) 17.39
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell (1995) 10.16
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Targeted cancer therapy. Nature (2004) 7.81
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science (2005) 5.31
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
The cancer biomarker problem. Nature (2008) 4.64
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med (2012) 4.15
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (2009) 3.89
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest (2004) 3.70
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity (1999) 2.31
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell (2001) 2.09
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A (2010) 2.06
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol (2002) 1.60
STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J (1998) 1.47
Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat Cell Biol (2008) 1.47
Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene (2004) 1.44
The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med (2006) 1.43
Retracted Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem (2002) 1.33
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 1.26
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res (2004) 1.23
Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem (2001) 1.20
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res (2010) 1.17
Retracted STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci (2005) 1.17
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem (2010) 1.14
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem (2005) 1.07
Unphosphorylated STAT and heterochromatin protect genome stability. FASEB J (2010) 1.05
The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res (2008) 1.02
It's diagnostics, stupid. Cell (2010) 0.95
A high-definition view of functional genetic variation from natural yeast genomes. Mol Biol Evol (2014) 2.10
IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol (2012) 1.68
Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene (2004) 1.44
The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med (2006) 1.43
Retracted Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem (2002) 1.33
Regulation of cyclin D1 RNA stability by SNIP1. Cancer Res (2008) 1.33
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics (2011) 1.27
Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem (2001) 1.20
Differential protein modulation in midguts of Aedes aegypti infected with chikungunya and dengue 2 viruses. PLoS One (2010) 1.14
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem (2010) 1.14
First report in a river in France of the benthic cyanobacterium Phormidium favosum producing anatoxin-a associated with dog neurotoxicosis. Toxicon (2005) 1.11
Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res (2005) 1.11
The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J Biol Chem (2006) 1.08
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem (2005) 1.07
Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer (2010) 1.07
Transcriptional regulation by a DNA-associated form of cyclin D1. Mol Biol Cell (2005) 1.06
A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J Biomed Biotechnol (2009) 1.05
Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci (2008) 1.02
Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. J Biol Chem (2011) 1.02
The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res (2008) 1.02
The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell (2011) 1.02
The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry (2006) 1.01
c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer (2011) 0.97
Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem (2012) 0.96
Quercitrin: an antileishmanial flavonoid glycoside from Kalanchoe pinnata. Planta Med (2006) 0.95
Retracted Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle (2010) 0.92
Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor. Mol Cancer (2010) 0.87
Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood (2003) 0.87
Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. J Pathol (2014) 0.85
Isolation and characterization of Psalmopeotoxin I and II: two novel antimalarial peptides from the venom of the tarantula Psalmopoeus cambridgei. FEBS Lett (2004) 0.85
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer (2011) 0.84
Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum. Protein Sci (2006) 0.84
Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi. Toxicon (2004) 0.83
Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol (2012) 0.82
Retracted Phosphorylation of the p52 NF-κB subunit. Cell Cycle (2010) 0.81
STAT3 as a new autophagy regulator. JAKSTAT (2013) 0.79
Affinity capture using chimeric membrane proteins bound to magnetic beads for rapid ligand screening by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom (2009) 0.78
Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells. Horm Mol Biol Clin Investig (2012) 0.77
Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. Proteomics Clin Appl (2014) 0.77
Kalanchosine dimalate, an anti-inflammatory salt from Kalanchoe brasiliensis. J Nat Prod (2006) 0.76
Nanospray analysis of the venom of the tarantula Theraphosa leblondi: a powerful method for direct venom mass fingerprinting and toxin sequencing. Rapid Commun Mass Spectrom (2004) 0.76
Circulating miRNAs as new activators of the JAK-STAT3 pathway. JAKSTAT (2013) 0.75
[Transient transformation as a permanent oncogenic loop]. Med Sci (Paris) (2010) 0.75
Intestinal cell targeting of a stable recombinant Cu-Zn SOD from Cucumis melo fused to a gliadin peptide. J Biotechnol (2012) 0.75
An unusual cleavage reaction of a peptide observed during dithiotreitol and tris(2-carboxyethyl)phosphine reduction: application to sequencing of HpTx2 spider toxin using nanospray tandem mass spectrometry. Rapid Commun Mass Spectrom (2004) 0.75
Two-step OFFGEL approach for effective peptide separation compatible with iTRAQ labeling. Proteomics (2013) 0.75